BridgeBio Pharma Operating Expenses 2018-2024 | BBIO
BridgeBio Pharma operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
BridgeBio Pharma Annual Operating Expenses
(Millions of US $) |
| 2023 |
$617 |
| 2022 |
$590 |
| 2021 |
$646 |
| 2020 |
$483 |
| 2019 |
$307 |
| 2018 |
$184 |
| 2017 |
$44 |
BridgeBio Pharma Quarterly Operating Expenses
(Millions of US $) |
| 2024-09-30 |
$194 |
| 2024-06-30 |
$178 |
| 2024-03-31 |
$211 |
| 2023-12-31 |
$179 |
| 2023-09-30 |
$162 |
| 2023-06-30 |
$148 |
| 2023-03-31 |
$128 |
| 2022-12-31 |
$131 |
| 2022-09-30 |
$129 |
| 2022-06-30 |
$154 |
| 2022-03-31 |
$175 |
| 2021-12-31 |
$179 |
| 2021-09-30 |
$152 |
| 2021-06-30 |
$148 |
| 2021-03-31 |
$168 |
| 2020-12-31 |
$128 |
| 2020-09-30 |
$128 |
| 2020-06-30 |
$125 |
| 2020-03-31 |
$102 |
| 2019-12-31 |
$92 |
| 2019-09-30 |
$81 |
| 2019-06-30 |
$69 |
| 2019-03-31 |
$64 |
| 2018-12-31 |
|
| 2018-09-30 |
$41 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
